KromaTiD’s Dark Lab Files: A Blog
Unbiased Visualization of Structural Rearrangements
DNA double-strand breaks (DSBs) and potential misrepair events can result from the use of gene editing tools like CRISPR/Cas systems. These misrepairs are associated with perilous structural variations in the genome which can endanger the long-term success of gene and cell therapy programs. Genomic [...]
New Genotoxicity Concerns in Nickase-Based Editing Systems
In the context of gene editing applications, genotoxicity may be defined as, “the property of an agent able to alter the genetic function within a cell causing unwanted mutations/effects, which may lead to functional impairment (e.g., cancer, therapy impairment, differentiation impairment).”1 Viewed from this [...]
KromaTiD Webinar | Combining Synthetic and Evolutionary Biology Reveals DNA Therapy to Combat Cancer Chemoresistance
Register below for the KromaTiD Webinar | Combining Synthetic and Evolutionary Biology Reveals DNA Therapy to Combat Cancer Chemoresistance Drug resistance is still an ongoing challenge for successful cancer treatment. Innovative approaches to understand and counteract the mechanisms of drug resistance are needed. In [...]
The Longer-Term Effects of CAR-T Therapy
CAR T cell therapies have achieved substantial improvements in the prognoses of patients fighting advanced hematological malignancies, demonstrating robust efficacy in inducing durable remissions. While the focus has predominantly been on acute adverse events, more research is needed on the long-term consequences of these [...]
Mast Cells and Dendritic Cells as Cellular Immune Checkpoints
Solid tumors, with their intricate immune microenvironment, pose a formidable challenge to immunotherapy. Within this complex landscape, mast cells (MCs) and dendritic cells (DCs) emerge as important players influencing the resistance mechanisms that impede the immune system's effectiveness against cancer1. Can their activities in [...]
Pairing Immunotherapies: CAR-T and NK Cells
While immune checkpoint blockade therapies targeting T cells have shown promise, limitations arise in cases of tumor escape mechanisms, including HLA-I downregulation. Loss of HLA-I can render T cell therapies less effective. Combining NK cells with T cell-based therapies may help overcome this limitation. [...]